● Recruiting

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Condition: Chronic Spontaneous Urticaria · Sponsor: Novartis Pharmaceuticals

PhaseN/A

Planned participants350

Who can joinAll sexes, 18 Years to 100 Years

Healthy volunteersNo

About this study

This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (1)

Novartis

East Hanover, New Jersey, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07408219